Further, we demonstrated that LMB‐100 administration resulted in increased numbers of active circulating CD4 and CD8 T cells, and identified specific changes in serum cytokines and peripheral CD4 T cell subsets associated with CLS, the major toxicity of iTox therapies. The gene discussed is CD4; the disease is capillary leak syndrome.